News Sentiment

TBPH sentiment intelligence

Theravance Biopharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 16.93 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

72/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+0.0% over one week, +2.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co.

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 72/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend inactive 2.1% over four weeks
Fair value 45.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 9
TradingView 7
Finviz 3
PR Newswire 3
Moomoo 2
Investing.com 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Deals and strategy 18
Market update 17
Earnings 15
Balance sheet 4
Analyst action 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Kavout | AI Direct company coverage

Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future

Zymeworks is strategically pivoting beyond its oncology focus with the $929 million acquisition of Theravance Biopharma, gaining the FDA-approved COPD therapy, Yupelri. This move aligns with current biopharma M&A trends emphasizing de-risked, cash-generating assets to address pat

Tone
Positive 67/100
Event
Deals and strategy
Published
06 Jul 2026 08:41
Source
Kavout | AI
Finviz Direct company coverage

TBPH - Theravance Biopharma Inc Options

This article provides a detailed financial overview of Theravance Biopharma Inc. (TBPH), including its latest stock performance, market capitalization, key financial ratios, and insider/institutional ownership data. It presents various metrics such as P/E, sales growth, profit ma

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 08:41
Source
Finviz
Stock Titan Direct company coverage

TBPH SEC Filings - Theravance Bioph 10-K, 10-Q, 8-K Forms

This page provides a comprehensive overview of Theravance Biopharma (TBPH) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. Recent filings detail equity grants to executives, a patent settlement for YUPELRI® extending generic availability to 2

Tone
Positive 62/100
Event
Market update
Published
04 Jul 2026 02:40
Source
Stock Titan
Finviz Direct company coverage

TBPH - Theravance Biopharma Inc Short Interest

This article provides a detailed overview of Theravance Biopharma Inc (TBPH) stock, focusing on various financial metrics, short interest data, and performance indicators. It includes information on the company's market capitalization, income, sales, P/E ratio, short interest per

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:11
Source
Finviz
Finviz Direct company coverage

TBPH - Theravance Biopharma Inc Latest SEC Filings

This article provides detailed financial data and performance metrics for Theravance Biopharma Inc (TBPH), including its latest stock close, market capitalization, income, sales, and various financial ratios. It also outlines insider ownership, institutional ownership, and short

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 19:40
Source
Finviz
Market source Direct company coverage

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

Theravance Biopharma has announced a definitive agreement to be acquired by Zymeworks for $17.00 per share in cash, totaling approximately $929 million in equity value. In addition to the cash payment, Theravance Biopharma shareholders will receive a contingent value right (CVR)

Tone
Positive 74/100
Event
Balance sheet
Published
02 Jul 2026 09:41
Source
Market source
Stock Titan Direct company coverage

Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales

Funds associated with Eli Samaha, managed by Madison Avenue Partners, LP, have significantly reduced their stake in Theravance Biopharma (TBPH) through open-market sales. Over three days, the funds sold a total of 336,697 shares at weighted average prices around $17 per share. De

Tone
Negative 34/100
Event
Deals and strategy
Published
01 Jul 2026 23:40
Source
Stock Titan
PMLiVE Direct company coverage

Zymeworks to acquire Theravance Biopharma in deal worth $929m

Zymeworks has announced its acquisition of Theravance Biopharma in a deal valued at approximately $929 million. This strategic move grants Zymeworks ownership of Yupelri, a key treatment for Chronic Obstructive Pulmonary Disease (COPD), broadening its portfolio. The acquisition a

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jul 2026 09:39
Source
PMLiVE
Arthur Cox LLP Direct company coverage

Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks

Arthur Cox advised Theravance Biopharma, Inc. on its definitive agreement to be acquired by Zymeworks Inc. for approximately US$929 million. The transaction values Theravance Biopharma at US$17.00 per share, plus a contingent value right for future proceeds from ampreloxetine. Th

Tone
Positive 71/100
Event
Deals and strategy
Published
01 Jul 2026 08:39
Source
Arthur Cox LLP
Pharmaceutical Technology Direct company coverage

Zymeworks agrees to buy Theravance Biopharma for $929m

Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma for approximately $929 million (C$1.32bn). Theravance Biopharma shareholders will receive $17 per share plus a contingent value right for 80% of net proceeds from future monetization

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 06:40
Source
Pharmaceutical Technology
AKM.RU Direct company coverage

Canadian Zymeworks acquires American Theravance Biopharma for $929 million

Canadian biotech company Zymeworks Inc. has agreed to acquire American Theravance Biopharma Inc. for $929 million, with the transaction expected to close in the second half of 2026. This acquisition supports Zymeworks' strategy to diversify its portfolio and optimize product valu

Tone
Neutral 50/100
Event
Deals and strategy
Published
30 Jun 2026 18:43
Source
AKM.RU
TradingView Direct company coverage

Theravance Stock Down 3% After Zymeworks Announces Buyout

Theravance Biopharma's stock dropped 3% after announcing an all-cash acquisition by Zymeworks Inc. for approximately $929 million. The deal follows a strategic review by Theravance after its lead candidate, ampreloxetine, failed in a pivotal phase III study. Shareholders will rec

Tone
Neutral 50/100
Event
Deals and strategy
Published
30 Jun 2026 13:11
Source
TradingView
The Business Journals Direct company coverage

After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion

Zymeworks is set to acquire Theravance Biopharma in a complex deal valued at less than $1 billion, marking the end of Theravance's three-decade legacy. Despite the sale, Theravance CEO Rick Winningham expressed ongoing commitment to creating impactful medicines. The acquisition h

Tone
Negative 40/100
Event
Deals and strategy
Published
30 Jun 2026 13:11
Source
The Business Journals
Moomoo Direct company coverage

Press Release: Zymeworks to Acquire Theravance Biopharma, Inc.

This press release announces Zymeworks' intent to acquire Theravance Biopharma, Inc. The acquisition is expected to create a stronger combined entity with an enhanced pipeline and capabilities. Further details about the terms of the acquisition and strategic rationale are anticip

Tone
Positive 71/100
Event
Deals and strategy
Published
30 Jun 2026 06:10
Source
Moomoo
PharmExec.com Direct company coverage

Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma

This article details two significant pharmaceutical acquisitions: Zymeworks' agreement to acquire Theravance Biopharma for approximately $929 million, primarily for its commercial COPD asset Yupelri and Irish tax attributes, and Ipsen's plan to acquire Kartos Therapeutics for up

Tone
Positive 72/100
Event
Deals and strategy
Published
29 Jun 2026 14:41
Source
PharmExec.com
Benzinga Direct company coverage

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

Zymeworks announced it will acquire Theravance Biopharma for $929 million in an all-cash transaction, expected to close in the second half of 2026. This acquisition will add Yupelri, a COPD treatment, to Zymeworks' commercial portfolio, giving it a 35% share of U.S. net profits f

Tone
Neutral 50/100
Event
Deals and strategy
Published
29 Jun 2026 13:41
Source
Benzinga
BioXconomy Direct company coverage

Zymeworks makes bold move with $929m Theravance Biopharma buy

Zymeworks has announced a $929 million acquisition of Theravance Biopharma, marking its entry into the respiratory disease sector. The deal centers on Yupelri, an FDA-approved COPD therapy, and is financed through a non-recourse arrangement, including a $350 million note and Ther

Tone
Neutral 50/100
Event
Deals and strategy
Published
29 Jun 2026 13:41
Source
BioXconomy
Stocktwits Direct company coverage

Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders

Zymeworks is acquiring Theravance Biopharma for $929 million, with shareholders receiving $17.00 per share in cash and a contingent value right (CVR) for 80% of future net proceeds from ampreloxetine monetization. This deal, offering a 22% premium over Theravance's stock price on

Tone
Neutral 50/100
Event
Deals and strategy
Published
29 Jun 2026 12:41
Source
Stocktwits
Stock Titan Direct company coverage

Zymeworks to acquire Theravance Biopharma (NASDAQ: TBPH) in $929M cash and CVR deal

Zymeworks is set to acquire Theravance Biopharma for approximately $929 million in a cash and contingent value right (CVR) deal. Theravance shareholders will receive $17.00 per share in cash, representing a 22% premium to its March 3, 2026 closing price, plus a CVR entitling them

Tone
Positive 72/100
Event
Deals and strategy
Published
29 Jun 2026 10:41
Source
Stock Titan
TradingView Direct company coverage

Theravance Biopharma to Be Acquired by Zymeworks for $17 Per Share Plus CVR

Theravance Biopharma (TBPH) has entered into an agreement to be acquired by Zymeworks for $17.00 per share in cash plus a contingent value right (CVR). The CVR entitles holders to additional cash based on net licensing proceeds, a $50 million milestone, and 10% of net sales for a

Tone
Positive 71/100
Event
Balance sheet
Published
29 Jun 2026 10:41
Source
TradingView
grafa.com Direct company coverage

Zymeworks to acquire Theravance Biopharma for $929M

Zymeworks has agreed to acquire Theravance Biopharma for $17 per share in cash, valuing the company at approximately $929 million. Theravance shareholders will also receive a contingent value right for 80% of net proceeds from any ampreloxetine monetization over ten years. The tr

Tone
Positive 71/100
Event
Balance sheet
Published
29 Jun 2026 10:09
Source
grafa.com
GlobeNewswire Direct company coverage

Zymeworks to Acquire Theravance Biopharma, Inc.

Zymeworks Inc. announced a definitive agreement to acquire Theravance Biopharma, Inc. for $17.00 per share, approximately $929 million. The acquisition will add YUPELRI® (revefenacin), a treatment for COPD, to Zymeworks' portfolio, anticipated to generate around $60 million in an

Tone
Positive 70/100
Event
Deals and strategy
Published
29 Jun 2026 09:41
Source
GlobeNewswire